Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 834.2 INR -1.22% Market Closed
Market Cap: 42.3B INR
Section:
 

Relative Value

The Relative Value of one ORCHPHARMA stock under the Base Case scenario is hidden INR. Compared to the current market price of 834.2 INR, Orchid Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORCHPHARMA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
31
vs Industry
28
Median 3Y
4.5
Median 5Y
4
Industry
2.6
Forward
3.7
More Details
81
P/E
P/E
Price to Earnings
81
vs History
6
vs Industry
13
Median 3Y
43.4
Median 5Y
32
Industry
21.7
Forward
79.8
More Details
92.3
P/OCF
P/OCF
Price to OCF
92.3
vs History
25
vs Industry
1
Median 3Y
85.3
Median 5Y
28.7
Industry
16.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
3
Median 3Y
-38.4
Median 5Y
-57.6
Industry
22.5
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
34
vs Industry
22
Median 3Y
3.2
Median 5Y
2.9
Industry
2.3
More Details
5.3
EV/S
EV/S
Enterprise Value to Sales
5.3
vs History
30
vs Industry
28
Median 3Y
4.6
Median 5Y
4.3
Industry
2.9
Forward
3.8
More Details
13.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.2
vs History
33
vs Industry
20
Median 3Y
11.4
Median 5Y
10.5
Industry
5.5
More Details
64.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
64.4
vs History
4
vs Industry
12
Median 3Y
37.4
Median 5Y
24.6
Industry
13.1
Forward
49.1
More Details
134.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
134.8
vs History
1
vs Industry
10
Median 3Y
58.4
Median 5Y
38.1
Industry
16.6
Forward
93.2
More Details
94.1
EV/OCF
EV/OCF
Enterprise Value to OCF
94.1
vs History
30
vs Industry
1
Median 3Y
96.1
Median 5Y
29.4
Industry
15.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
4
Median 3Y
-19.8
Median 5Y
-28.2
Industry
19.1
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
36
vs Industry
23
Median 3Y
3.1
Median 5Y
2.5
Industry
1.9
More Details

Multiples Across Competitors

ORCHPHARMA Competitors Multiples
Orchid Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Orchid Pharma Ltd
NSE:ORCHPHARMA
42.3B INR 5.2 81 64.4 134.8
US
Eli Lilly and Co
NYSE:LLY
952.1B USD 16.1 51.9 34.8 37.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.4B USD 5.4 19.7 16.1 20.9
CH
Roche Holding AG
SIX:ROG
253.5B CHF 4.1 26.9 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 4.9 30.1 108.3 158.5
CH
Novartis AG
SIX:NOVN
205.7B CHF 4.6 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
245.7B USD 3.8 12.9 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 8.9 10.3
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.6B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
IN
Orchid Pharma Ltd
NSE:ORCHPHARMA
Average P/E: 29.7
81
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.9
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Orchid Pharma Ltd
NSE:ORCHPHARMA
Average EV/EBITDA: 403.6
64.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.4
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Orchid Pharma Ltd
NSE:ORCHPHARMA
Average EV/EBIT: 1 719.9
134.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3

See Also

Summary
ORCHPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ORCHPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ORCHPHARMA stock valuation using valuation multiples.
Wall Street Estimates
ORCHPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ORCHPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.